841 related articles for article (PubMed ID: 17496437)
1. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
2. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
3. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
4. TP53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy.
Wang XW; Harris CC
Cancer Surv; 1996; 28():169-96. PubMed ID: 8977035
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
[TBL] [Abstract][Full Text] [Related]
6. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.
Olivier M; Hussain SP; Caron de Fromentel C; Hainaut P; Harris CC
IARC Sci Publ; 2004; (157):247-70. PubMed ID: 15055300
[TBL] [Abstract][Full Text] [Related]
8. p53 from basic research to clinical applications.
Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
[TBL] [Abstract][Full Text] [Related]
9. Loss of TP53-DNA interaction induced by p.C135R in lung cancer.
Aranda M; Gonzalez-Nilo F; Riadi G; Díaz V; Perez J; Martel G; Hainaut P; Mimbacas A
Oncol Rep; 2007 Nov; 18(5):1213-7. PubMed ID: 17914575
[TBL] [Abstract][Full Text] [Related]
10. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer.
Ecke TH; Schlechte HH; Gunia S; Lenk SV; Loening SA
Urol Oncol; 2008; 26(5):470-3. PubMed ID: 18367114
[TBL] [Abstract][Full Text] [Related]
11. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
[TBL] [Abstract][Full Text] [Related]
12. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer.
Bennett WP; Hussain SP; Vahakangas KH; Khan MA; Shields PG; Harris CC
J Pathol; 1999 Jan; 187(1):8-18. PubMed ID: 10341702
[TBL] [Abstract][Full Text] [Related]
13. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in XPD and TP53 and mutation in human lung cancer.
Mechanic LE; Marrogi AJ; Welsh JA; Bowman ED; Khan MA; Enewold L; Zheng YL; Chanock S; Shields PG; Harris CC
Carcinogenesis; 2005 Mar; 26(3):597-604. PubMed ID: 15564288
[TBL] [Abstract][Full Text] [Related]
15. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides.
Soussi T; Béroud C
Hum Mutat; 2003 Mar; 21(3):192-200. PubMed ID: 12619105
[TBL] [Abstract][Full Text] [Related]
16. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
[TBL] [Abstract][Full Text] [Related]
17. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
18. Gene p53 mutations, protein p53, and anti-p53 antibodies as biomarkers of cancer process.
Lutz W; Nowakowska-Swirta E
Int J Occup Med Environ Health; 2002; 15(3):209-18. PubMed ID: 12462448
[TBL] [Abstract][Full Text] [Related]
19. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]